


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.*



**INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED**  
**領航醫藥及生物科技有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock Code: 399)**

**(I) POLL RESULTS OF THE SPECIAL GENERAL MEETINGS  
HELD ON 28 JUNE 2023; AND**  
**(II) EXTENSION OF LONG STOP DATE IN RESPECT OF  
AMENDMENT OF THE TERMS AND CONDITIONS  
OF THE CONVERTIBLE BONDS**

**POLL RESULTS OF THE SPECIAL GENERAL MEETING IN RELATION  
TO THE THIRD AMENDMENT**

The Board is pleased to announce that the resolution as set out in the Notice was duly passed by the Shareholders by way of poll at the SGM held on 28 June 2023.

References are made to (1) the circular (the “**Circular**”) of Innovative Pharmaceutical Biotech Limited (the “**Company**”) dated 12 June 2023 in relation to the Third Amendment; and (2) the notice of the special general meeting dated 12 June 2023 in relation to the Third Amendment (the “**Notice**”). Unless the context otherwise requires, terms defined in this announcement shall have the same meanings as those defined in the Circular.

## POLL RESULTS OF THE SPECIAL GENERAL MEETING IN RELATION TO THE THIRD AMENDMENT

The Board is pleased to announce that at the special general meeting held on 28 June 2023 in relation to the Third Amendment (the “**SGM**”), as more than 50% of the votes were cast in favour of the proposed ordinary resolution as set out in the Notice (“**Resolution**”), the Resolution was duly passed by the Shareholders by way of poll as ordinary resolution of the Company.

Tricor Tengis Limited, the Company’s branch share registrar, acted as the scrutineer for the purpose of the counting of votes at the SGM. The poll results of the resolution at the SGM are as follows:

ORDINARY RESOLUTION		For		Against	
		Number of Shares	%	Number of Shares	%
1.	To approve, among others, (a) the Third Amendment Deed and all the transactions contemplated thereunder; (b) the allotment and issue of the Conversion Shares upon exercise of the conversion rights attached to the Convertible Bonds under the Specific Mandate; and (c) any Director is authorized to do all such things and acts and execute all such documents, with full details as indicated in the notice of the Meeting.	598,947,590	100.00	0	0.00

As at the date of the SGM, a total of 1,464,193,024 Shares were in issue. As at the date of this announcement, Dr. Mao Yumin, being a substantial shareholder of the Company, holds 323,200,000 Shares directly and 7,770,810 Shares indirectly through China United Gene Investment Holdings Limited (“**China United Gene**”). Dr. Mao Yumin is also a director of certain subsidiaries of the Bondholder and holds approximately 7.94% of the issued shares of the Bondholder. In light of the above, Dr. Mao is materially interested in the Third Amendment. Hence, Dr. Mao Yumin and China United Gene were required to abstain and have abstained from voting on the Resolution at the SGM. Save as disclosed above, no Shareholders were required to abstain from voting on the resolution proposed at the SGM. Save as disclosed above, no party has stated its intention in the Circular that it would vote against or to abstain from voting on the Resolution at the SGM.

The directors of the Company, Ms. Jiang Nian, Mr. Gao Yuan Xing, Mr. Tang Rong, Ms. Wu Yanmin, Ms. Chen Weijun, Mr. Wang Rongliang and Mr. Chen Jinzhong, attended the SGM either in person or by electronic means.

## **EXTENSION OF LONG STOP DATE IN RESPECT OF AMENDMENT OF THE TERMS AND CONDITIONS OF THE CONVERTIBLE BONDS**

Pursuant to the Third Deed of Amendment, the parties to the Third Deed of Amendment shall fulfill the conditions to the Third Amendments on or before the Third Amendment Long Stop Date, being 28 June 2023, or such other date as the Company and the Bondholder may agree. In the event that any of the conditions is not fulfilled by the Third Amendment Long Stop Date, the Third Deed of Amendment shall automatically lapse and be of no further effect and the Company and the Bondholder shall be released from all obligations thereunder.

As additional time is required to fulfil all the condition precedents as set out in the Third Deed of Amendment, the Company and the Bondholder has entered into an extension letter to extend the Third Amendment Long Stop Date to 12 July 2023 or such other date as the Company and Bondholder may agree.

Save for the above, all other terms and conditions of the Third Deed of Amendment shall remain unchanged and continue in full force and effect.

By Order of the Board  
**Innovative Pharmaceutical Biotech Limited**  
**Gao Yuan Xing**  
*Executive Director*

Hong Kong, 28 June 2023

*As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director) and Mr. Chen Jinzhong (independent non-executive Director).*